AU2017232036A1 - Method for treating peyronie's disease - Google Patents
Method for treating peyronie's disease Download PDFInfo
- Publication number
- AU2017232036A1 AU2017232036A1 AU2017232036A AU2017232036A AU2017232036A1 AU 2017232036 A1 AU2017232036 A1 AU 2017232036A1 AU 2017232036 A AU2017232036 A AU 2017232036A AU 2017232036 A AU2017232036 A AU 2017232036A AU 2017232036 A1 AU2017232036 A1 AU 2017232036A1
- Authority
- AU
- Australia
- Prior art keywords
- plaque
- patient
- injecting
- mass
- low intensity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 208000004362 Penile Induration Diseases 0.000 title claims abstract description 30
- 208000020758 Peyronie disease Diseases 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 48
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 25
- 230000035939 shock Effects 0.000 claims abstract description 21
- 238000012360 testing method Methods 0.000 claims abstract description 21
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 18
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 18
- 230000002308 calcification Effects 0.000 claims abstract description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001722 verapamil Drugs 0.000 claims abstract description 12
- 230000010349 pulsation Effects 0.000 claims abstract description 8
- 230000017531 blood circulation Effects 0.000 claims description 16
- 210000001367 artery Anatomy 0.000 claims description 4
- 238000012285 ultrasound imaging Methods 0.000 claims description 4
- 210000003423 ankle Anatomy 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000002302 brachial artery Anatomy 0.000 claims description 3
- 238000009552 doppler ultrasonography Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 abstract description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract description 3
- 239000000480 calcium channel blocker Substances 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000012423 maintenance Methods 0.000 abstract 1
- 210000003899 penis Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 210000005226 corpus cavernosum Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010070653 Penile curvature Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005099 collagenase clostridium histolyticum Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 229940022743 xiaflex Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
METHOD FOR TREATING PEYRONIE'S DISEASE In a method of treating a patient having diffused plaque and a plaque mass associated with Peyronie's disease in a penile region, a battery of tests is performed to quantify an initial state of parameters associated with Peyronie's disease in the patient. Low intensity shock wave therapy is applied to the plaque mass in the penile region, thereby softening the plaque mass and disrupting any calcification in the plaque mass. Carbon dioxide is injected into the plaque mass. The battery of tests is repeated to quantify a current state of parameters associated with Peyronie's disease in the patient and the current state is compared to the initial state. The aforementioned treatment steps are repeated until the current state differs from the initial state by at least a predetermined amount. |Verapamill PERFORM BASELINE TEST BATTERY (112 APPLY LOW INTENSITY SHOCKWAVES AND COUNTER APPLY COUNTER PULSATION TREATMENT APPLY CARBOXY TREATMENT TO PLAQUE CONCENTRATION INJECT L-TYPE PHENYLALKYLAMINECLASS CALCIUM CHANNEL BLOCKER (VERAPAMIL) INTO PLAQUE CONCENTRATION REPEAT TEST BATTERY UFFICIEN 122 IMPROVEMENT OVER BASELINE? MAINTENANCE
Description
ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT
Invention Title: Method of Treating Peyronie's Disease
The following statement is a full description of this invention, including the best method of performing it known to us:
2017232036 18 Sep 2017
METHOD FOR TREATING PEYRONIE’S DISEASE BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to treatment methods and, more specifically, to a method of treating Peyronie’s disease.
[0003] 2. Description of the Related Art [0004] Peyronie’s disease (also known as induratio penis plastic) is an acquired inflammatory condition of the penis associated with penile curvature. It is a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. Scar tissue forms in the tunica albuginea, the thick sheath of tissue surrounding the corpora cavernosa causing pain, abnormal curvature, erectile dysfunction, indentation, loss of girth and shortening. The penile curvature of Peyronie's disease is caused by an inelastic scar, or plaque (which may include calcification), that shortens the involved aspect of the tunica albuginea of the corpora cavernosa during erection.
[0005] If left untreated, Peyronie's disease may cause fibrotic, nonexpansile thickening of relatively discrete areas of the corpora tunica, typically resulting in focal bend, pain or other functional or structural abnormalities of the erect penis. Surgery is one method of treating Peyronie’s disease. Surgery has the disadvantage of being expensive and occasionally resulting in unwanted complications. Several medical treatments have been applied, but results so far have been limited. Surgical treatments have also been used to treat Peyronie’s disease. Collagenase Clostridium histolyticum (marketed as Xiaflex), an injectable drug, is the most common medical treatment of Peyronie's disease. It is believed that this works by breaking down the excess collagen in the penis that causes Peyronie's disease. This drug has limited success and it can be quite expensive.
2017232036 18 Sep 2017 [0006] Therefore, there is a need for a reliable and inexpensive non-surgical treatment for Peyronie’s disease.
SUMMARY OF THE INVENTION [0007] The disadvantages of the prior art are overcome by the present invention which, in one aspect, is a method of treating a patient having diffused plaque and a plaque mass associated with Peyronie’s disease in a penile region, in which a battery of tests is performed to quantify an initial state of parameters associated with Peyronie’s disease in the patient. Low intensity shock wave therapy is applied to the plaque mass in the penile region, thereby softening the plaque mass and disrupting any calcification in the plaque mass. Carbon dioxide is injected into the plaque mass. The battery of tests is repeated to quantify a current state of parameters associated with Peyronie’s disease in the patient and the current state is compared to the initial state. The aforementioned treatment steps are repeated until the current state differs from the initial state by at least a predetermined amount.
[0008] In another aspect, the invention is a treatment method for a patient having a plaque mass associated with Peyronie’s disease in a penile region, in which a battery of tests is performed to quantify an initial state of parameters associated with Peyronie’s disease in the patient. Low intensity shock wave therapy is applied to a plaque mass in the penile region for about thirteen treatments over a period of seven to eight weeks including a two week break period of no low intensity shock wave treatment, thereby softening the plaque and disrupting calcification in the plaque mass. A plurality of doses of about 160 cc of carbon dioxide per dose is injected into the plaque mass for a total of 960 cc. A counter pulsation treatment is applied every five days during a period of seven weeks to the patient concurrently with the step of applying low intensity shock wave therapy to further disrupt calcification in the plaque mass. A therapeutically effective dose of Verapamil is injected into a dorsal area of the penile area after the step of applying low intensity shock wave therapy to the plaque mass. The battery of tests is repeated to quantify a current state of parameters associated with Peyronie’s disease in the patient and comparing the current state to the initial state. The aforementioned
2017232036 18 Sep 2017 steps are repeated until the current state differs from the initial state by at least a predetermined amount.
[0009] These and other aspects of the invention will become apparent from the following description of the preferred embodiments taken in conjunction with the following drawings. As would be obvious to one skilled in the art, many variations and modifications of the invention may be effected without departing from the spirit and scope of the novel concepts of the disclosure.
BRIEF DESCRIPTION OF THE FIGURES OF THE DRAWINGS [0010] FIG. 1 is a schematic diagram showing treatment of a dorsal plaque.
[0011] FIG. 2 is a flow chart showing a treatment protocol.
DETAILED DESCRIPTION OF THE INVENTION [0012] A preferred embodiment of the invention is now described in detail. Referring to the drawings, like numbers indicate like parts throughout the views. Unless otherwise specifically indicated in the disclosure that follows, the drawings are not necessarily drawn to scale. As used in the description herein and throughout the claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise: the meaning of “a,” “an,” and “the” includes plural reference, the meaning of “in” includes “in” and “on.” [0013] As shown in FIG. 1, Peyronie’s disease causes curvature of the penis 10 as the result of a plaque mass 14 forming in the dorsal tunica of the penis 10. It can also result from calcification of the corpus cavernosa 12 in the penis 10. As will be shown below, the present treatment protocol includes several steps for improving blood flow through the affected area, along with injecting a therapeutically effective dose of an L-type phenylalkylamine class
2017232036 18 Sep 2017 calcium channel blocker (such as Verapamil) 102 into the plaque mass 14 and also injecting carbon dioxide 104 into the plaque mass 14.
[0014] In one embodiment of a treatment protocol for Peyronie’s disease, as shown in FIG. 2, an initial test battery is performed on the patient 110 in order to establish a baseline. This test battery typically includes imaging the plaque with an ultrasound imaging device, measuring blood flow in penile blood vessels of the patient with a duplex Doppler ultrasonography blood flow device and measuring pulse wave velocity in a brachial artery and an ankle artery of the patient. Circulatory blood flow velocity in the patient is tested typically with a duplex Doppler. U.S. Patent No. 6,251,076, issued to Hovland et al., discloses one method of determining blood flow velocity in a penile artery and is incorporated herein by reference for the purpose of disclosing methods of determining blood flow velocity.
[0015] Low intensity shock wave therapy is applied to the plaque mass in the penile region 112. This softens the plaque mass and disrupts calcification in the plaque mass. In doing so, low intensity shockwave (LISW) therapy is applied to the plaque mass for about thirteen treatments over a period of seven to eight weeks, including a two week break period off no low intensity shock wave treatment. In the low intensity shockwave treatment (LISW), shock waves having a maximum energy of 0.09 mJmm2 are applied with a local applicator to the penile area once per day for two or three days per week over a course of five weeks. U.S. Publication No. US-2015/0073312-Al, filed by Ein-Gal, discloses one method of low intensity shockwave treatment and is incorporated herein by reference for the purpose of disclosing low intensity shockwave treatment. In a typical treatment, about 300 pulses are applied per minute over the course of between 10 minutes and 20 minutes. The LISW treatment stimulates neovascularization and improves penile blood flow and endothelial function when applied to the corpora cavernosa.
[0016] Counter pulsation treatment is applied twice per week during a period of at least ten weeks 114, which can be done concurrently with the low intensity shock wave therapy. This further disrupts calcification in the plaque mass and improves blood flow. The course of external counter-pulsation treatment includes applying external counter-pulsation treatments to the patient for a predetermined number of days per week for a predetermined number of
2017232036 18 Sep 2017 weeks. In applying the course of external counter-pulsation treatments an electrocardiogram (ECG) sensing device is applied to the patient and the ECG is sensed. U.S. Patent Nos. 7,314,478 and 7,314,478, both issued to Hui, disclose a counter-pulsation apparatus and method for controlling the apparatus and is incorporated herein by reference for the purpose of disclosing counter-pulsation methods. An inflatable cuff is applied to at least one of the patient’s calf, lower thigh, upper thigh or buttocks. Typically, cuffs are applied to both of the lower thighs and to both of the upper thighs. Counter pulsations are applied to the cuffs by inflating the cuffs to a pressure of about 300 mm Hg during a diastole sensed by the ECG. Pressure is then rapidly released from the cuffs during onset of the systole, as sensed by the ECG. Counter-pulsations are performed repeatedly during a treatment sessions that last about one hour, which are performed twice per week over a course of ten weeks. (It should be noted that the term “ECP” is sometimes confused with “EECP,” which is a registered a trademark for a brand of ECP. However, the EECP brand can be employed as the type of ECP used.
[0017] Carbon dioxide is then injected into the plaque mass 116, which is referred to as “carboxy therapy.” In this step, about 960cc of carbon dioxide is injected into one or both of the corpus cavemosum, the dorsal tunica of the patient or other area of plaque mass (typically in injections of about 160cc each in several different locations). This is typically performed twice per week, but 48 hours apart, for twelve consecutive weeks. Typically, the carboxy therapy is performed after the low intensity shockwave treatment and the counter pulsation treatment steps to reduce the dispersal of the carbon dioxide in the injected tissues. U.S. Patent No. 9,132,245, issued to Mantell, discloses a carboxy therapy application and is incorporated here by reference to disclose one device and method for administering carboxy therapy. The carboxy therapy infuses carbon dioxide into the tissues, causing the body to interpret the presence of the carbon dioxide as an oxygen deficiency, which results in the production of vascular endothelial growth factors in the tissues. This encourages vascular growth and local reduction in fat tissue, which results in increased blood flow to the corpora cavernosa.
[0018] An L-type phenylalkylamine class calcium channel blocker, of the type known generically as “Verapamil,” is injected into a calcified plaque area of the penile area 118.
2017232036 18 Sep 2017
Typically, in this step 0.625 mg to 2.5 mg of Verapamil is injected into a dorsal tunica of the patient. About 12 Verapamil treatments are administered at a frequency of one every 14 days.
[0019] The test battery is repeated 120 to quantify patient treatment progress. If there has not been sufficient improvement over the baseline test, then the treatment steps are repeated 122. Indicia of sufficient improvement include the observance of no plaque in the ultrasound imaging and the observance of a doubling in blood flow in the affected area. Once the desired result is achieved, the patient can return periodically for examination and maintenance treatments 124 if such treatments are indicated.
[0020] The methods of the present invention could also be useful in treating calcification in an individual's hand, or other extremity.
[0021] The above described embodiments, while including the preferred embodiment and the best mode of the invention known to the inventor at time of filing, are given as illustrative examples only. It will be readily appreciated that many deviations may be made from the specific embodiments disclosed in this specification without departing from the spirit and scope of the invention. Accordingly, the scope of the invention is to be determined by the claims below rather than being limited to the specifically described embodiments above.
[0022] Throughout this specification, unless the context requires otherwise, the word comprise, or variations such as comprises or comprising, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0023] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this specification.
Claims (20)
1. A method of treating a patient having diffused plaque and a plaque mass associated with Peyronie’s disease in a penile region, comprising the steps of:
(a) performing a battery of tests to quantify an initial state of parameters associated with Peyronie’s disease in the patient;
(b) applying low intensity shock wave therapy to the plaque mass in the penile region, thereby softening the plaque mass and disrupting any calcification in the plaque mass;
(c) injecting carbon dioxide into the plaque mass after the step of applying low intensity shock wave therapy;
(d) repeating the battery of tests to quantify a current state of parameters associated with Peyronie’s disease in the patient and comparing the current state to the initial state; and (e) until the current state differs from the initial state by at least a predetermined amount, repeating steps (b) through (d).
2. The method of Claim 1, further comprising the step of applying external counterpulsation therapy to the patient concurrently with the step of applying low intensity shock wave therapy, further softening the plaque mass and disrupting any calcification in the plaque mass.
3. The method of Claim 1, wherein the step of applying counter-pulsation therapy comprises applying a counter pulsation treatment about twice per week during a period of at least ten weeks.
4. The method of Claim 1, wherein the step of applying low intensity shock wave therapy to the plaque mass comprises applying low intensity shockwave therapy to the plaque
2017232036 18 Sep 2017 mass for about thirteen treatments over a period of seven to eight weeks, including a two week break period off no low intensity shock wave treatment.
5. The method of Claim 1, further comprising the step of injecting a therapeutically effective dose of Verapamil into a calcified plaque area of the penile area.
6. The method of Claim 5, wherein the step of injecting a therapeutically effective dose of Verapamil is performed after the step of applying low intensity shock wave therapy to the plaque mass.
7. The method of Claim 5, wherein the step of injecting a therapeutically effective dose of Verapamil comprises the step of injecting between 0.625 mg to 2.5 mg into a dorsal tunica of the patient.
8. The method of Claim 5, wherein the step of injecting a therapeutically effective dose of Verapamil comprises performing about 12 treatments at a frequency of every 14 days.
9. The method of Claim 1, wherein the step of injecting carbon dioxide into the plaque mass comprises injecting about 960cc of carbon dioxide into a dorsal tunica of the patient.
10. The method of Claim 1, wherein the step of injecting carbon dioxide into the plaque mass comprises injecting about 960cc of carbon dioxide into a corpus cavemosum of the patient.
11. The method of Claim 1, wherein the step of injecting carbon dioxide into the plaque mass is performed twice per week, but 48 hours apart, for twelve consecutive weeks.
12. The method of Claim 1, wherein the battery of tests includes imaging the plaque with an ultrasound imaging device and the current state differs from the initial state by the predetermined amount when no plaque is observed.
ίο
2017232036 18 Sep 2017
13. The method of Claim 1, wherein the battery of tests includes measuring blood flow in penile blood vessels of the patient with a duplex Doppler ultrasonography blood flow device and the current state differs from the initial state by the predetermined amount when about a doubling in blood flow is observed.
14. The method of Claim 1, wherein the battery of tests includes measuring pulse wave velocity in a brachial artery and an ankle artery of the patient.
15. A treatment method for a patient having a plaque mass associated with Peyronie’s disease in a penile region, comprising the steps of:
(a) performing a battery of tests to quantify an initial state of parameters associated with Peyronie’s disease in the patient;
(b) applying low intensity shock wave therapy to the plaque mass in the penile region for about thirteen treatments over a period of seven to eight weeks including a two week break period of no low intensity shock wave treatment, thereby softening the plaque and disrupting calcification in the plaque mass;
(c) applying a counter pulsation treatment twice per week for at least ten weeks to the patient concurrently with the step of applying low intensity shock wave therapy to further disrupt calcification in the plaque mass;
(d) injecting a plurality of doses of about 160 cc of carbon dioxide per dose into the plaque mass for a total of 960 cc after the steps of applying low intensity shock wave therapy and applying a counter pulsation treatment;
(e) injecting a therapeutically effective dose of Verapamil into a dorsal area of the penile area after the step of applying low intensity shock wave therapy to the plaque mass;
(f) repeating the battery of tests to quantify a current state of parameters associated with Peyronie’s disease in the patient and comparing the current state to the initial state; and (g) until the current state differs from the initial state by at least a predetermined amount, repeating steps (b) through (e).
2017232036 18 Sep 2017
16. The treatment method of Claim 15, wherein the step of injecting a therapeutically effective dose of Verapamil comprises the step of injecting between 0.625 mg to 2.5 mg into the dorsal tunica of the patient and performing about 12 treatments at a frequency of every 14 days.
17. The treatment method of Claim 15, wherein the step of injecting carbon dioxide into the plaque mass comprises injecting the carbon dioxide into at least one of a dorsal tunica of the patient and a corpus cavemosum of the patient twice per week, but 48 hours apart, for twelve consecutive weeks.
18. The treatment method of Claim 15, wherein the battery of tests includes imaging the plaque with an ultrasound imaging device and the current state differs from the initial state by the predetermined amount when no plaque is observed.
19. The treatment method of Claim 15, wherein the battery of tests includes measuring blood flow in penile blood vessels of the patient with a duplex Doppler ultrasonography blood flow device and the current state differs from the initial state by the predetermined amount when about a doubling in blood flow is observed.
20. The treatment method of Claim 15, wherein the battery of tests includes measuring pulse wave velocity in a brachial artery and an ankle artery of the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017232036A AU2017232036B2 (en) | 2017-09-18 | 2017-09-18 | Method for treating peyronie's disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017232036A AU2017232036B2 (en) | 2017-09-18 | 2017-09-18 | Method for treating peyronie's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017232036A1 true AU2017232036A1 (en) | 2019-04-04 |
| AU2017232036B2 AU2017232036B2 (en) | 2024-03-07 |
Family
ID=65908638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017232036A Active AU2017232036B2 (en) | 2017-09-18 | 2017-09-18 | Method for treating peyronie's disease |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2017232036B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484724B2 (en) | 2015-09-30 | 2022-11-01 | Btl Medical Solutions A.S. | Methods and devices for tissue treatment using mechanical stimulation and electromagnetic field |
-
2017
- 2017-09-18 AU AU2017232036A patent/AU2017232036B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484724B2 (en) | 2015-09-30 | 2022-11-01 | Btl Medical Solutions A.S. | Methods and devices for tissue treatment using mechanical stimulation and electromagnetic field |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017232036B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11602540B2 (en) | Method for stimulating blood flow in a penile region of a patient | |
| US10426835B2 (en) | Method for treating Peyronie's disease | |
| US20210212882A1 (en) | Method for treating organic erectile dysfunction | |
| US20180147111A1 (en) | Medical protocol for improving human sexual function | |
| RU2385169C1 (en) | Method of treating children with posttraumatic limb injures in postoperative period | |
| RU2609054C1 (en) | Method for treating erectile dysfunction "julia" | |
| AU2017232036B2 (en) | Method for treating peyronie's disease | |
| EP3456275B1 (en) | Carbon dioxide for treating peyronie`s disease | |
| CA2979368A1 (en) | Therapeutic combination of low intensity shock waves and carbon dioxide for the treatment of peyronie's disease | |
| AU2017232035A1 (en) | Method for treating organic erectile dysfunction | |
| RU2773101C1 (en) | Method for treating lateral epicondylitis | |
| RU2612496C1 (en) | Method of treating neuropathy of ulnar in cubital channel | |
| RU2543286C1 (en) | Method of treating children with consequences of injuries of upper and lower extremities | |
| RU2525619C1 (en) | Method of treating patients with chronic prostatitis | |
| RU2203696C2 (en) | Method for treating varicose low extremity veins by means of injections | |
| RU2157111C1 (en) | Device for making vein puncture and method for treating lower extremity varicose veins | |
| RU2190993C1 (en) | Method for performing healing cosmetic rarefaction massage | |
| RU2368400C1 (en) | Treatment method of prostate gland benign hyperplasia | |
| CA2980053A1 (en) | Use of a combination of counter-pulsations, low intensity shock waves and carbon dioxide for treating organic erectile dysfunction | |
| Selem et al. | Impact of integrated neuromuscular inhibition technique versus electro-acupuncture stimulation of posterior tibial nerve in males with chronic pelvic pain of myofascial origin | |
| SU833264A1 (en) | Method of treating vascular diseases of extremities | |
| Angelov et al. | Special cases of sclerotherapy | |
| SU1690789A1 (en) | Method for treatment of peripheral vessels of the limbs | |
| Sajjad | Dry Needling: An Evidence Based Approach to Treat Myofascial Trigger Point | |
| SU1736510A1 (en) | Method of treating post-trauma contractures of soft tissue structures |